Cited by 391PARP inhibition in cancer therapyDNA Repair MechanismsBRCA gene mutations in cancer

The DOI matches its Crossref record; 551 of the 559 references it cites were found in a registry or an index.

Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond

Open access

Curtin, Nicola J., Szabo, Csaba·2013·Molecular Aspects of Medicine

DOI 10.1016/j.mam.2013.01.006PMC PMC3657315

Open this paper in CoChat — free account

Abstract

The aim of this article is to describe the current and potential clinical translation of pharmacological inhibitors of poly(ADP-ribose) polymerase (PARP) for the therapy of various diseases. The first section of the present review summarizes the available preclinical and clinical data with PARP inhibitors in various forms of cancer. In this context, the role of PARP in single-strand DNA break repair is relevant, leading to replication-associated lesions that cannot be repaired if homologous recombination repair (HRR) is defective, and the synthetic lethality of PARP inhibitors in HRR-defective cancer. HRR defects are classically associated with BRCA1 and 2 mutations associated with familial breast and ovarian cancer, but there may be many other causes of HRR defects. Thus, PARP inhibitors may be the drugs of choice for BRCA mutant breast and ovarian cancers, and extend beyond these tumors if appropriate biomarkers can be developed to identify HRR defects. Multiple lines of preclinical data demonstrate that PARP inhibition increases cytotoxicity and tumor growth delay in combination with temozolomide, topoisomerase inhibitors and ionizing radiation. Both single agent and combination clinical trials are underway. The final part of the first section of the present review summarizes the current status of the various PARP inhibitors that are in various stages of clinical development. The second section of the present review summarizes the role of PARP in selected non-oncologic indications. In a number of severe, acute diseases (such as stroke, neurotrauma, circulatory shock and acute myocardial infarction) the clinical translatability of PARP inhibition is supported by multiple lines of preclinical data, as well as observational data demonstrating PARP activation in human tissue samples. In these disease indications, PARP overactivation due to oxidative and nitrative stress drives cell necrosis and pro-inflammatory gene expression, which contributes to disease pathology. Accordingly, multiple lines of preclinical data indicate the efficacy of PARP inhibitors to preserve viable tissue and to down-regulate inflammatory responses. As the clinical trials with PARP inhibitors in various forms of cancer progress, it is hoped that a second line of clinical investigations, aimed at testing of PARP inhibitors for various non-oncologic indications, will be initiated, as well.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.mam.2013.01.006

Cites

551 of 551 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: Protective effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation
Cuzzocrea, S., Zingarelli, B., Gilad, E., Hake, P. W., Salzman, A. L., & Szabó, C. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01417-9 · Cited by 85
Retracted
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Nitric Oxide and Peroxynitrite in Health and Disease
Pacher, P., Beckman, J. S., & Liaudet, L. (2007) · Physiological Reviews · doi:10.1152/physrev.00029.2006 · Cited by 6,390
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Self-citation
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276
Heart-Lung Transplantation
Yarbrough, W. M., Robbins, R. C., & Mallidi, H. R. (2016) · CRC Press eBooks · doi:10.3109/9781439802571-25 · Cited by 2,161
Peroxynitrite: biochemistry, pathophysiology and development of therapeutics
Szabó, C., Ischiropoulos, H., & Radi, R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2222 · Cited by 2,134
Self-citation

Show all 559 references

Research works printed but not linked: 3

Du, 2007, Local administration of the poly (ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice, J. Neurotrauma, 24, 1399, 10.1089/neu.2007.0305 · DOI
Komjáti, 2005, Poly(ADP-ribose) polymerase inhibitors as therapeutic agents for stroke and brain trauma. Current Drug Targets, CNS Neurol. Disord., 4, 179
Miknyoczki, 2003, Chemopotentiation of temozlomide, irinotecan and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor, Mol. Cancer Ther., 2, 371

Sorted by citations

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Regulated necrosis: the expanding network of non-apoptotic cell death pathways
Berghe, T. V., Linkermann, A., Jouan-Lanhouet, S., Walczak, H., & Vandenabeele, P. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3737 · Cited by 1,735
NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus
Cantó, C., Menzies, K. J., & Auwerx, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.023 · Cited by 1,648
Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects
Badawy, A. A.-B. (2017) · International Journal of Tryptophan Research · doi:10.1177/1178646917691938 · Cited by 1,158
Essential versus accessory aspects of cell death: recommendations of the NCCD 2015
Galluzzi, L., Bravo-San Pedro, J. M., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Alnemri, E. S., Altucci, L., Andrews, D., Annicchiarico-Petruzzelli, M., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.137 · Cited by 1,002
Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease
Re, D. P. D., Amgalan, D., Linkermann, A., Liu, Q., & Kitsis, R. N. (2019) · Physiological Reviews · doi:10.1152/physrev.00022.2018 · Cited by 994
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J. J., Takeda, S., Morris, J., Teicher, B. A., Doroshow, J. H., & Pommier, Y. G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 777
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Pommier, Y. G., O’Connor, M. J., & Bono, J. S. D. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9246 · Cited by 755
PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes
Gupte, R., Liu, Z., & Kraus, W. L. (2017) · Genes & Development · doi:10.1101/gad.291518.116 · Cited by 681
“The discovery that cancers with BRCA1/2 mutations are sensitive to PARPis has sparked great interest in developing these drugs to treat ovarian and breast cancer (Curtin and Szabo 2013).”
Background
Regulated necrosis: disease relevance and therapeutic opportunities
Conrad, M., Angeli, J. P. F., Vandenabeele, P., & Stockwell, B. R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.6 · Cited by 630
Poly(ADP-ribose) polymerase inhibition: past, present and future
Curtin, N. J., & Szabó, C. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0076-6 · Cited by 595
Self-citation
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozović, A., Gonçalves, A. C., Jurkovičová, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento‐Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 541
Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance
Bai, P. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.01.034 · Cited by 457
Click Chemistry in Proteomic Investigations
Parker, C. G., & Pratt, M. R. (2020) · Cell · doi:10.1016/j.cell.2020.01.025 · Cited by 392
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
Thorsell, A. G., Ekblad, T., Karlberg, T., Löw, M., Pinto, A. F., Tresaugues, L., Moche, M., Cohen, M. S., & Schuler, H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00990 · Cited by 369
Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation
Gibson, B. A., Zhang, Y., Jiang, H., Hussey, K. M., Shrimp, J. H., Lin, H., Schwede, F., Yu, Y., & Kraus, W. L. (2016) · Science · doi:10.1126/science.aaf7865 · Cited by 381
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
Ge, Y., Tian, T., Huang, S., Wan, F., Li, J., Li, S., Wang, X., Yang, H., Hong, L., Wu, N., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00568-6 · Cited by 300
Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition
Murai, J., Zhang, Y., Morris, J., Ji, J. J., Takeda, S., Doroshow, J. H., & Pommier, Y. G. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.210146 · Cited by 300
Poly(ADP-ribose) signaling in cell death
Virág, L., Robaszkiewicz, A., Rodriguez-Vargas, J. M., & Oliver, F. J. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.007 · Cited by 273
Which cell death modality wins the contest for photodynamic therapy of cancer?
Mishchenko, T. A., Balalaeva, I. V., Gorokhova, A. A., Vedunova, M. V., & Krysko, D. V. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04851-4 · Cited by 293
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors
Hopkins, T. A., Shi, Y., Rodriguez, L. E., Solomon, L. R., Donawho, C. K., DiGiammarino, E. L., Panchal, S. C., Wilsbacher, J. L., Gao, W., Olson, A. M., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0191-t · Cited by 270
Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle
Pirinen, E., Cantó, C., Jo, Y. S., Morato, L., Zhang, H., Menzies, K. J., Williams, E. G., Mouchiroud, L., Moullan, N., Hagberg, C., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.04.002 · Cited by 254
“First, chronic Parib treatment could induce genomic instability (Curtin and Szabo, 2013).”
BackgroundInfluential
Readers of poly(ADP-ribose): designed to be fit for purpose
Teloni, F., & Altmeyer, M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1383 · Cited by 269
Trapping Poly(ADP-Ribose) Polymerase
Shen, Y., Aoyagi-Scharber, M., & Wang, B. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222448 · Cited by 230
Microbiome—Microbial Metabolome—Cancer Cell Interactions in Breast Cancer—Familiar, but Unexplored
Mikó, E., Kovàcs, T., Sebő, É., Tóth, J., Csonka, T., Ujlaki, G., Sipos, A., Szabó, J., Méhes, G., & Bai, P. (2019) · Cells · doi:10.3390/cells8040293 · Cited by 228
Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases
Berger, N. A., Besson, V. C., Boulares, A. H., Bürkle, A., Chiarugi, A., Clark, R. S. B., Curtin, N. J., Cuzzocrea, S., Dawson, T. M., Dawson, V. L., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13748 · Cited by 219
Self-citation
The Promise of Proteomics for the Study of ADP-Ribosylation
Daniels, C. M., Ong, S., & Leung, A. K. L. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.06.012 · Cited by 204
Poly(ADP-ribose): PARadigms and PARadoxes
Bürkle, A., & Virág, L. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.12.010 · Cited by 205
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
JONES, P. G., Wilcoxen, K., Rowley, M., & Toniatti, C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5018237 · Cited by 192
Tankyrases: Structure, Function and Therapeutic Implications in Cancer
Haikarainen, T., Krauss, S. J. K., & Lehtiö, L. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140630101525 · Cited by 192
Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule
Zhao, Q., Lan, T., Su, S., & Rao, Y. (2018) · Chemical Communications · doi:10.1039/c8cc07813k · Cited by 187
PARPs in lipid metabolism and related diseases
Szántó, M., Gupte, R., Kraus, W. L., Pacher, P., & Bai, P. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101117 · Cited by 181
Discovery and Characterization of (8 S ,9 R )-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1 H -1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3 H -pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
Wang, B., Chu, D., Feng, Y., Shen, Y., Aoyagi-Scharber, M., & Post, L. E. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01498 · Cited by 186
PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis
Mukhopadhyay, P., Horváth, B., Rajesh, M., Varga, Z. V., Gariani, K., Ryu, D., Cao, Z., Holovac, E., Park, O., Zhou, Z., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.10.023 · Cited by 168
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Wang, Q., Peng, H., Qi, X., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0199-6 · Cited by 162
Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders
Henning, R. J., Bourgeois, M., & Harbison, R. D. (2018) · Cardiovascular Toxicology · doi:10.1007/s12012-018-9462-2 · Cited by 158
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy
Papeo, G., Posteri, H., Borghi, D., Busel, A. A., Caprera, F., Casale, E., Ciomei, M., Cirla, A., Corti, E., D’Anello, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00680 · Cited by 147
The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling
Sipos, A., Ujlaki, G., Mikó, E., Maka, E., Szabó, J., Uray, K., Krasznai, Z. T., & Bai, P. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00295-2 · Cited by 153
Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function
Feng, F. Y.-C., Bono, J. S. D., Rubin, M. A., & Knudsen, K. E. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.016 · Cited by 133
From old alkylating agents to new minor groove binders
Puyo, S., Montaudon, D., & Pourquier, P. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.07.006 · Cited by 133
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA -Mutant Ovarian Cancer
Kummar, S., Oza, A. M., Fleming, G. F., Sullivan, D. M., Gandara, D. R., Naughton, M. J., Villalona-Calero, M. A., Morgan, R. J., Szabó, P., Youn, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2565 · Cited by 131
Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited
Lupo, B., & Trusolino, L. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.004 · Cited by 135
PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
Min, A., & Im, S. (2020) · Cancers · doi:10.3390/cancers12020394 · Cited by 134
Poly (ADP-Ribose) Polymerase-1 Is a Key Mediator of Liver Inflammation and Fibrosis
Mukhopadhyay, P., Rajesh, M., Cao, Z., Horváth, B., Park, O., Wang, H., Erdélyi, K., Holovac, E., Wang, Y., Liaudet, L., et al. (2013) · Hepatology · doi:10.1002/hep.26763 · Cited by 125
Poly(ADP-ribose) polymerases as modulators of mitochondrial activity
Bai, P., Nagy, L., Fodor, T., Liaudet, L., & Pacher, P. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.11.003 · Cited by 120
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment
Peng, X., Sun, Z., Kuang, P., & Chen, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112831 · Cited by 120
An update on PARP inhibitors for the treatment of cancer
Hall, M., & Benafif, S. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s30793 · Cited by 112
PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers
Murai, J., & Pommier, Y. G. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055914 · Cited by 114
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
Lorenzo, S. B. D., Patel, A. G., Hurley, R. M., & Kaufmann, S. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00228 · Cited by 116
PARP1 Inhibitors: Antitumor Drug Design
Maluchenko, N. V., Kotova, E. Y., Kulaeva, O. I., Kirpichnikov, M. P., & Studitskiy, V. M. (2015) · Acta Naturae · doi:10.32607/20758251-2015-7-3-27-37 · Cited by 112
PARP inhibition protects mitochondria and reduces ROS production via PARP-1-ATF4-MKP-1-MAPK retrograde pathway
Hocsák, E., Szabó, V., Kálmán, N., Antus, C., Cseh, A. M., Sümegi, K., Erős, K., Hegedüs, Z., Gallyas, F., Sümegi, B., et al. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.04.018 · Cited by 111
PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
Wang, L., Liang, C., Li, F., Guan, D., Wu, X., Fu, X., Lü, A., & Zhang, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102111 · Cited by 116
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
Jette, N., Kumar, M., Radhamani, S., Arthur, G., Goutam, S., Yip, S., Kolinsky, M. P., Williams, G. J., Bose, P., & Lees‐Miller, S. P. (2020) · Cancers · doi:10.3390/cancers12030687 · Cited by 112
The rise and fall of poly(ADP-ribose): An enzymatic perspective
Pascal, J. M., & Ellenberger, T. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.04.008 · Cited by 107
Adipose tissue NAD+-homeostasis, sirtuins and poly(ADP-ribose) polymerases -important players in mitochondrial metabolism and metabolic health
Jokinen, R., Pirnes-Karhu, S., Pietiläinen, K. H., & Pirinen, E. (2017) · Redox Biology · doi:10.1016/j.redox.2017.02.011 · Cited by 103
DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer
Velic, D., Couturier, A. M., Ferreira, M., Rodrigue, A., Poirier, G. G., Fleury, F., & Masson, J. (2015) · Biomolecules · doi:10.3390/biom5043204 · Cited by 106
Poly(ADP‐ribose) Polymerase 1 (PARP1) in Atherosclerosis: From Molecular Mechanisms to Therapeutic Implications
Xu, S., Bai, P., Little, P. J., & Liu, P. (2013) · Medicinal Research Reviews · doi:10.1002/med.21300 · Cited by 99
The role of melatonin on doxorubicin-induced cardiotoxicity: A systematic review
Najafi, M., Shayesteh, M. R. H., Mortezaee, K., Farhood, B., & Haghi‐Aminjan, H. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117173 · Cited by 96
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System
Parrish, K. E., Cen, L., Murray, J., Calligaris, D., Kizilbash, S. H., Mittapalli, R. K., Carlson, B. L., Schroeder, M. A., Sludden, J., Boddy, A. V., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0553 · Cited by 93
Self-citation
Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy
Yuan, Z., Chen, S., Sun, Q., Wang, N., Li, D., Miao, S., Gao, C., Chen, Y., Tan, C., & Jiang, Y. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.05.058 · Cited by 90
Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers
Cao, C.-G., Yang, J., Chen, Y. X., Zhou, P., Wang, Y., Du, W., Zhao, L., & Chen, Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00821 · Cited by 88
PARP inhibitors for anticancer therapy
Curtin, N. J. (2014) · Biochemical Society Transactions · doi:10.1042/bst20130187 · Cited by 89
Self-citation
Chemical Methods for Encoding and Decoding of Posttranslational Modifications
Chuh, K. N., Batt, A. R., & Pratt, M. R. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2015.11.006 · Cited by 90
The role of ADP-ribose metabolism in metabolic regulation, adipose tissue differentiation, and metabolismPreprint
Szántó, M., & Bai, P. (2020) · Genes & Development · doi:10.1101/gad.334284.119 · Cited by 91
E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling
McGonigle, S., Chen, Z., Wu, J., Chang, P., Kolber, D. L., Ackermann, K. E., Twine, N. C., Shie, J., Miu, J. T., Huang, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5846 · Cited by 88
PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis
Karicheva, O., Rodríguez-Vargas, J. M., Wadier, N., Martin-Hernandez, K., Vauchelles, R., Magroun, N., Tissier, A., Schreiber, V., & Dantzer, F. (2016) · Oncotarget · doi:10.18632/oncotarget.11627 · Cited by 92
Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis
Krug, S., Parveen, S., & Bishai, W. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660916 · Cited by 85
PARP inhibitors: polypharmacology versus selective inhibition
Ekblad, T., Camaioni, E., Schuler, H., & Macchiarulo, A. (2013) · FEBS Journal · doi:10.1111/febs.12298 · Cited by 82
RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma
Viziteu, E., Klein, B., Basbous, J., Lin, Y., Hirtz, C., Gourzonès, C., Tiers, L., Bruyer, A., Vincent, L., Grandmougin, C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.54 · Cited by 78
Drug resistance‐related microRNAs in osteosarcoma: Translating basic evidence into therapeutic strategies
Chen, R., Wang, G., Zheng, Y., Hua, Y., & Cai, Z. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14064 · Cited by 77
Tryptophan metabolism and disposition in cancer biology and immunotherapy
Badawy, A. A. ‐. (2022) · Bioscience Reports · doi:10.1042/bsr20221682 · Cited by 80
Roles of N-Methyl-D-Aspartate Receptors (NMDARs) in Epilepsy
Chen, S., Xu, D., Liu, F., Fang, Z. H., Wang, X., & Li, M. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.797253 · Cited by 75
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer
Kummar, S., Wade, J. L., Oza, A. M., Sullivan, D. M., Chen, A. P., Gandara, D. R., Ji, J. J., Kinders, R. J., Wang, L., Allen, D. E., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0335-x · Cited by 74
Reverse the Resistance to PARP Inhibitors
Kim, Y., Kim, A., Sharip, A., Sharip, A., Jiang, J., Yang, Q., & Xie, Y. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.17240 · Cited by 75
Mitochondrial poly(ADP-ribose) polymerase: The Wizard of Oz at work
Brunyánszki, A., Szczęsny, B., Virág, L., & Szabó, C. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.02.024 · Cited by 73
Tryptophan Metabolism: A Versatile Area Providing Multiple Targets for Pharmacological Intervention
Badawy, A. A.-B. (2019) · Egyptian Journal of Basic and Clinical Pharmacology · doi:10.32527/2019/101415 · Cited by 78
PARP14 inhibits microglial activation via LPAR5 to promote post-stroke functional recovery
Tang, Y., Liu, J., Wang, Y., Yang, L., Han, B., Zhang, Y., Bai, Y., Shen, L., Li, M., Jiang, T., et al. (2020) · Autophagy · doi:10.1080/15548627.2020.1847799 · Cited by 72
PARP, transcription and chromatin modeling
Marjanović, M. P., Crawford, K., & Ahel, I. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.09.014 · Cited by 72
Transcription and DNA Damage: Holding Hands or Crossing Swords?
D’Alessandro, G., & di Fagagna, F. D. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.11.002 · Cited by 72
Successes and Challenges of PARP Inhibitors in Cancer Therapy
Ricks, T. K., Chiu, H.-J., Ison, G., Kim, G., McKee, A. E., Kluetz, P. G., & Pazdur, R. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00222 · Cited by 70
Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation
Boraei, A. T. A., Singh, P. K., Sechi, M., & Satta, S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111621 · Cited by 69
Nicotinamide adenine dinucleotide homeostasis and signalling in heart disease: Pathophysiological implications and therapeutic potential
Mericskay, M. (2015) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2015.10.004 · Cited by 69
Metabolic roles of poly(ADP-ribose) polymerases
Vida, A., Márton, J., Mikó, E., & Bai, P. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.12.009 · Cited by 69
The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma
Chen, H., Yang, M., Wang, Q., Song, F., Li, X., & Chen, K. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1608132 · Cited by 66
Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
de Haan, R., van den Heuvel, M. M., van Diessen, J., Peulen, H. M. U., van Werkhoven, E. D., de Langen, A. J., Lalezari, F., Pluim, D., Verwijs-Janssen, M., Vens, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2551 · Cited by 64
Nudix hydrolases degrade protein-conjugated ADP-ribose
Daniels, C. M., Thirawatananond, P., Ong, S., Gabelli, S. B., & Leung, A. K. L. (2015) · Scientific Reports · doi:10.1038/srep18271 · Cited by 64
Repositioning PARP inhibitors for SARS‐CoV‐2 infection(COVID‐19); a new multi‐pronged therapy for acute respiratory distress syndrome?
Curtin, N. J., Bànyai, K., Thaventhiran, J. E. D., Quesne, J. P. C. L., Helyes, Z., & Bai, P. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15137 · Cited by 61
Self-citation
SIRT6 interacts with TRF2 and promotes its degradation in response to DNA damage
Rizzo, A., Iachettini, S., Salvati, E., Zizza, P., Maresca, C., D’Angelo, C., Benarroch, D., Capolupo, A., Gaudio, F. D., Cosconati, S., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1202 · Cited by 66
A Quantitative Assay Reveals Ligand Specificity of the DNA Scaffold Repair Protein XRCC1 and Efficient Disassembly of Complexes of XRCC1 and the Poly(ADP-ribose) Polymerase 1 by Poly(ADP-ribose) Glycohydrolase
Kim, I.-K., Stegeman, R. A., Brosey, C. A., & Ellenberger, T. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.624718 · Cited by 57
BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
Kan, C. E., & Zhang, J. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.05.037 · Cited by 54
New paradigms in the repair of oxidative damage in human genome: mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins
Dutta, A., Yang, C., Sengupta, S., MITRA, S. P., & Hegde, M. L. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1820-z · Cited by 56
NAD+: A key metabolic regulator with great therapeutic potential
Sultani, G., Samsudeen, A., Osborne, B., & Turner, N. A. (2017) · Journal of Neuroendocrinology · doi:10.1111/jne.12508 · Cited by 54
Discovery and Structure–Activity Relationship of Novel 2,3-Dihydrobenzofuran-7-carboxamide and 2,3-Dihydrobenzofuran-3(2 H )-one-7-carboxamide Derivatives as Poly(ADP-ribose)polymerase-1 Inhibitors
Patel, M. R., Bhatt, A., Steffen, J. D., Chergui, A., Murai, J., Pommier, Y. G., Pascal, J. M., Trombetta, L. D., Fronczek, F. R., & Talele, T. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5002502 · Cited by 52
Differentiation-Associated Downregulation of Poly(ADP-Ribose) Polymerase-1 Expression in Myoblasts Serves to Increase Their Resistance to Oxidative Stress
Oláh, G., Szczęsny, B., Brunyánszki, A., López-García, I. A., Gerő, D., Radak, Z. O., & Szabó, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134227 · Cited by 51
Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin
Vareki, S. M., Rytelewski, M., Figueredo, R., Chen, D., Ferguson, P. J., Vincent, M. D., Min, W., Zheng, X., & Koropatnick, J. D. (2014) · Oncotarget · doi:10.18632/oncotarget.1916 · Cited by 53
Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors
Haikarainen, T., Narwal, M., Joensuu, P., & Lehtiö, L. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400292s · Cited by 51
Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells
Hirai, T., Saito, S., Fujimori, H., Matsushita, K., Nishio, T., Okayasu, R., & Masutani, M. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.07.062 · Cited by 51
Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity
Reilly, S. W., Puentes, L. N., Wilson, K., Hsieh, C., Weng, C.-C., Makvandi, M., & Mach, R. H. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00576 · Cited by 51
7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors
Cincinelli, R., Musso, L., Merlini, L., Giannini, G., Vesci, L., Milazzo, F. M., Carenini, N., Perego, P., Penco, S., Artali, R., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.12.031 · Cited by 50
PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4+ T cell function
Ghonim, M. A., Pyakurel, K., Ibba, S. V., Al-Khami, A. A., Wang, J., Rodrı́guez, P. C., Rady, H. F., El‐Bahrawy, A. H., Lammi, M. R., Mansy, M. S., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0583-0 · Cited by 49

Authors: Curtin, N. J., & Szabo, C.
Affiliations: Newcastle University (GB)
Corresponding author: Curtin, Nicola J.
ORCID: Curtin, Nicola J.
Venue: Molecular Aspects of Medicine
Publisher: Elsevier BV
Published: 2013-12
Volume: 34
Issue: 6
Pages: 1217-1256
ISSN: 0098-2997 (ISSN-L)
DOI: 10.1016/j.mam.2013.01.006
PMC: PMC3657315
OpenAlex: W2017171454
Cited by: 369
References: 559
Citations by year: 2026: 9 · 2025: 17 · 2024: 12 · 2023: 22 · 2022: 25 · 2021: 25 · 2020: 37 · 2019: 31 · 2018: 26 · 2017: 32 · 2016: 38 · 2015: 50 · 2014: 24 · 2013: 21
FWCI: 4.93
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Molecular Aspects of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Newcastle University ePrints (Newcastle Univesity)
Funders: National Institutes of Health
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: PARP inhibitors, poly(ADP-ribose) polymerase, synthetic lethality, homologous recombination deficiency, BRCA mutations, breast cancer, ovarian cancer, temozolomide combination therapy, topoisomerase inhibitors, ionizing radiation, oxidative stress, nitrative stress, necrosis, inflammation, stroke, neurotrauma, shock, acute myocardial infarction, clinical translation
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Enzyme Inhibitors, Humans, Neoplasms, Poly(ADP-ribose) Polymerases, Radiation-Sensitizing Agents, Stroke, Translational Research, Biomedical, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks